321 related articles for article (PubMed ID: 32087733)
1. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.
Nived P; Jönsson G; Settergren B; Einarsson J; Olofsson T; Jørgensen CS; Skattum L; Kapetanovic MC
Arthritis Res Ther; 2020 Feb; 22(1):36. PubMed ID: 32087733
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
3. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy.
Nived P; Nagel J; Saxne T; Geborek P; Jönsson G; Skattum L; Kapetanovic MC
Vaccine; 2017 Jun; 35(29):3639-3646. PubMed ID: 28552512
[TBL] [Abstract][Full Text] [Related]
4. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
[No Abstract] [Full Text] [Related]
5. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
Crnkic Kapetanovic M; Saxne T; Jönsson G; Truedsson L; Geborek P
Arthritis Res Ther; 2013 Oct; 15(5):R171. PubMed ID: 24286269
[TBL] [Abstract][Full Text] [Related]
6. Isolating polysaccharide IgG pneumococcal antibody responses by pre-adsorption of conjugate vaccine serotypes: A modified approach for the conjugate vaccine era.
Mohamed OE; Williams L; Wong GK; Hayes M; Townsend K; Harding S; Huissoon AP
J Immunol Methods; 2020 Nov; 486():112846. PubMed ID: 32882318
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
Alten R; Bingham CO; Cohen SB; Curtis JR; Kelly S; Wong D; Genovese MC
BMC Musculoskelet Disord; 2016 May; 17():231. PubMed ID: 27229685
[TBL] [Abstract][Full Text] [Related]
10. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial.
Nguyen MTT; Lindegaard H; Hendricks O; Jørgensen CS; Kantsø B; Friis-Møller N
J Rheumatol; 2017 Dec; 44(12):1794-1803. PubMed ID: 28966211
[TBL] [Abstract][Full Text] [Related]
11. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.
Migita K; Akeda Y; Akazawa M; Tohma S; Hirano F; Ideguchi H; Kozuru H; Jiuchi Y; Matsumura R; Suematsu E; Miyamura T; Mori S; Fukui T; Izumi Y; Iwanaga N; Tsutani H; Saisyo K; Yamanaka T; Ohshima S; Mori N; Matsumori A; Takahi K; Yoshizawa S; Kawabe Y; Suenaga Y; Ozawa T; Hamada N; Komiya Y; Matsui T; Furukawa H; Oishi K
Arthritis Res Ther; 2015 Dec; 17():357. PubMed ID: 26653668
[TBL] [Abstract][Full Text] [Related]
12. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.
Bahuaud M; Beaudouin-Bazire C; Husson M; Molto A; Launay O; Batteux F; Dougados M
Hum Vaccin Immunother; 2018 Jun; 14(6):1464-1470. PubMed ID: 29432051
[TBL] [Abstract][Full Text] [Related]
14. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.
Crnkic Kapetanovic M; Saxne T; Truedsson L; Geborek P
Arthritis Res Ther; 2013 Jan; 15(1):R1. PubMed ID: 23286772
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.
Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Sinisalo M
Hum Vaccin Immunother; 2019; 15(12):2910-2913. PubMed ID: 31216225
[TBL] [Abstract][Full Text] [Related]
17. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
Hamaluba M; Kandasamy R; Upreti SR; Subedi GR; Shrestha S; Bhattarai S; Gurung M; Pradhan R; Voysey M; Gurung S; Pradhan S; Thapa AK; Maharjan R; Kiran U; Kerridge SA; Hinds J; van der Klis F; Snape MD; Murdoch DR; Kelly S; Kelly DF; Adhikari N; Thorson S; Pollard AJ
Lancet Infect Dis; 2015 Apr; 15(4):405-14. PubMed ID: 25701560
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
[TBL] [Abstract][Full Text] [Related]
20. Response to pneumococcal conjugate and polysaccharide vaccination in children with rheumatic disease.
Jensen L; Christensen AE; Nielsen S; Pedersen FK; Rosthøj S; Jørgensen CS; Poulsen A
Scand J Immunol; 2022 Feb; 95(2):e13118. PubMed ID: 34768311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
